Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for Endothelial Dysfunction in ADPKD
NCT01853553Phase 3Completed
- Sponsor
- University of Colorado Denver
- Start
- Jul 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of spironolactone in autosomal dominant polycystic kidney disease (ADPKD), sponsored by University of Colorado Denver. Started Jul 2013; status: completed.
02
Drugs
spironolactone
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT01853553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01853553.